News stories about Madrigal Pharmaceuticals (NASDAQ:MDGL) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.9916554916206 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) traded up $0.58 during midday trading on Thursday, reaching $98.40. The company’s stock had a trading volume of 83,000 shares, compared to its average volume of 110,586. The company has a market cap of $1,380.00, a PE ratio of -40.00 and a beta of 0.80. Madrigal Pharmaceuticals has a 1-year low of $13.09 and a 1-year high of $101.00.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.11. research analysts predict that Madrigal Pharmaceuticals will post -2.57 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on MDGL shares. Zacks Investment Research upgraded Madrigal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a report on Wednesday, December 20th. Evercore ISI began coverage on Madrigal Pharmaceuticals in a report on Friday, September 22nd. They issued an “outperform” rating and a $65.00 price target on the stock. Roth Capital increased their price objective on Madrigal Pharmaceuticals from $82.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, December 11th. HC Wainwright began coverage on Madrigal Pharmaceuticals in a research note on Wednesday, November 29th. They issued a “buy” rating and a $54.00 price objective on the stock. Finally, JMP Securities increased their price objective on Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the stock an “outperform” rating in a research note on Friday, October 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $129.00.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-madrigal-pharmaceuticals-mdgl-stock-price.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.